Study of breast cancer markers after CDK4/6 inhibitor treatment
Part of Cancer, Skin clinical trials.
This study looks at lab markers and clinical features in people with certain types of breast cancer who are being treated with, or have already been treated with a CDK4/6 inhibitor like abemaciclib (ciclib-based therapy). It aims to understand patterns that may help doctors better characterize breast cancer after these treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that is ER-positive and HER2-negative (or HR-positive with node-positive, higher-risk early disease)
- You are currently on, or have been treated with ciclib (a CDK4/6 inhibitor)–based therapy
- You are an adult and you can and will review consent details and sign the study consent form
- You are not pregnant and you are not nursing
- You are willing and able to follow the study’s procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with a common type of breast cancer that is hormone-receptor-positive and HER2-negative, and has a high risk of coming back. It looks at how well patients take a type of targeted therapy (CDK4/6 inhibitors) combined with hormone therapy after surgery, to help prevent recurrence.
This study looks at patients whose breast cancer returns after starting a CDK4/6 inhibitor (like abemaciclib or ribociclib) along with hormone therapy. The goal is to understand why the cancer comes back and find better ways to treat it.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This phase 2 trial compares ribociclib, palbociclib, and abemaciclib to see how each one affects your body’s immune response in estrogen- and/or progesterone-receptor–positive, HER2-negative early breast cancer. If you fit the stage and health requirements, joining could help doctors learn which treatment best “modulates” the immune system.
This trial tests whether a newer targeted therapy (dalpiciclib) causes fewer side effects than two similar drugs (abemaciclib and ribociclib) in people with early-stage, hormone receptor-positive, HER2-negative breast cancer after surgery. The goal is to find a better-tolerated treatment to reduce the risk of cancer returning.
Hear when a new Anatomic Stage IV Breast Cancer AJCC v8 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.